Ripple Therapeutics receives funding support to advance R&D efforts in ophthalmic therapeutics

TORONTO, ON, CANADA / APRIL 27, 2022 - Ripple Therapeutics is pleased to announce that it is receiving advisory services and up to $500,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of Ripple’s lead product, IBE-814 IVT for the treatment of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO).  The project will entail analyzing the data generated from our ongoing clinical trial and the scale up of the product for the next stages on the path to commercialization.

“We are pleased to secure funding and advisory support from NRC IRAP," stated Wendy Naimark, Ripple Therapeutic’s Chief Technology Officer. "Work completed under this program will significantly enhance Ripple’s research and development efforts in ophthalmic therapeutics with controllable, sustainable drug delivery”.

Ripple is currently enrolling patients in RIPPLE-1, a Phase II clinical trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting DME and RVO patients.  The trial seeks to provide a much-needed treatment option: a safer steroid implant with an extended clinical benefit.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery.  The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients.  Ripple has a full product pipeline in development. www.rippletherapeutics.com

 

 

Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

RIPPLE-ABBVIE OPHTHALMIC DRUG DELIVERY PANEL

February 12, 2026
Our Chief Technology Officer, Wendy Naimark , was pleased to be speaking with AbbVie Directors, Allison Hoch, PhD, MBA, Director of Global Alliances and Amy Hopkin Director of Search & Evaluation for AbbVie Eyecare, on a Harnessing Innovation & Collaboration to Accelerate Ophthalmic Drug Delivery Panel at the 4th Annual Ophthalmic Drug Delivery Summit on Thursday January 29th in San Francisco, CA. 🗣️ Topic: Unlocking Biotech-Pharma Collaboration: How Agile Small Teams & Experienced Pharma Combine Strengths to Accelerate Innovation & Deliver Real-World Impact. Areas Covered: ✅ Co-developing platforms, managing device timelines and regulatory alignment in combo products ✅ Leveraging the speed and innovation of biotech startups with deep experience and resources of pharma ✅ Continuous learning through cooperation during diligence, development planning and execution phases ✅ The importance of proactive, transparent communication across functions to anticipate challenges and optimize for success View Presentation

Ripple Therapeutics Enters Collaboration with Bausch + Lomb

November 25, 2025
TORONTO, CANADA / November 25, 2025 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.